SNY - Alnylam Pharmaceuticals Tries To Rally The Troops With A Blizzard Of New R&D Candidates
There are two criticisms you’ll never read about Alnylam (ALNY) — that management is insufficiently promotional of the company, and that it doesn’t have enough pipeline candidates/ideas. Always a company with many irons in the fire, Alnylam hosted an R&D day Thursday that was a little like drinking from a fire hose in terms of the sheer number of early-stage projects and potential clinical compounds.
In terms of valuation-driving news, though, there wasn’t too much to come out of this event. I am not generally fond of assigning values to compounds before Ph